Resource use and costs in a Swedish cohort of patients with Parkinson's disease

Abstract

We estimated resource use and costs in patients with Parkinson's disease (PD), thereby providing baseline data for future economic evaluations of therapeutic interventions. Data were collected from medical records of a South Swedish cohort of 127 PD patients during 1 year (1996) and a mailed questionnaire inquiring about cost-related consequences and resource use in 1996 and in 2000. Annual costs were calculated based on prevalence and expressed in SEK (monetary value of the year 2000). Direct health care costs averaged approximately SEK 29,000 ( approximately USD 2,900; EUR 3,200) per patient per year, of which drugs were the most costly component. Nonmedical direct costs were higher than direct health care costs, averaging approximately SEK 43,000 ( approximately USD 4,300; EUR 4,800) per patient per year, and costs due to lost production were approximately SEK 52,000 ( approximately USD 5,200; EUR 5,800) per patient per year. The mean total annual cost for PD in our sample approximated SEK 124,000 ( approximately USD 12,400; EUR 13,800) per patient. These findings are roughly within the same range as estimates from other countries and show that PD causes a considerable societal burden. In addition to other outcomes, evaluations of the economic implications of new therapeutic interventions are highly warranted. In this perspective, the present study provides valuable baseline data.

Estimating the value of novel interventions for Parkinson's disease: An early decision-making model with application to dopamine cell replacement

“…Resource use and cost data for the model were derived from an earlier cost-of-illness study, expressing costs (including those related to co-morbidities and complications) by "off"-phase HY stages under standard therapy [17]. Recent data indicate that dyskinesias may contribute to PD-related costs also after controlling for the effects of HY stages [34].…”

“…However, the extent to which this applies to the model presented here is not completely evident due to methodological discrepancies. As opposed to our baseline cost-of-illness study [17], but similarly to other decision models for PD [11], Péchevis et al [34] based their estimates on "on"-phase HY stages and excluded costs associated with co-morbidities. This point to a need for further descriptive studies to clarify whether complications such as dyskinesias need to be accounted for in future model revisions and applications or if such practice will result in double-accounting, as compared to our current model.…”

“…5 Increase in cost-per-QALY in both directions of the sensitivity analysis despite cost saving in the base case are due to non-linear cost development across HY stages [17]. 6 Only differences in costs are regarded.…”

Cost and Efficacy of Therapies for Advanced Parkinson's Disease

“…Several studies have been performed to date in different countries to analyze the economic and social burden of PD. According to this literature, the main drivers of the total direct cost of PD are hospitalization and drug costs (Keranen et al, 2003;O'Brien et al, 2009) and the main drivers of total indirect cost are nursing care and productivity loss (Dengler et al, 2006;Hagell et al, 2002;O'Brien et al, 2009). In the United States, the annual economic impact of PD was estimated in 2007 at $10.78 billion, being 58% of this amount related to direct medical costs ($6.22 billion) (O'Brien et al, 2009).…”

“…Within this, 76% of the costs were related to nursing care and the loss of productivity. In Sweden resource use and costs in patients with PD were collected from medical records of a cohort of 127 patients (Hagell et al, 2002) in 1996 (year 2000 costs). Direct health care costs averaged approximately €3,200 per patient per year, of which drugs were the most costly component.…”